跳至主要内容
临床试验/JPRN-jRCTs031180094
JPRN-jRCTs031180094已完成2 期

The efficacy of Leukotriene receptor antagonist for human rectal aberrant crypt foci: nonrandomized open label controlled trial

Misawa Noboru0 个研究点目标入组 40 人开始时间: 2019年1月25日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

During the study period, 30 patients in the LTRA group and 10 patients in the no-treatment follow-up group were enrolled. In the LTRA group, the number of ACF decreased significantly from 7.9 +/- 3.0 (pre-treatment) to 5.5 +/- 3.3 (post-treatment, after 8 weeks of LTRA treatment) (p<0.001). While the number of ACFs in the no-treatment follow-up group was 11.0 +/- 5.4 at the baseline to 11.4+/- 5.8 after 8 weeks, no significant change the number of ACFs was observed (p=0.578).

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 30age old 至 < 80age old(—)
性别
All

入选标准

  • 1.Patients with resectable polyps.
  • 2.Patients with more than 5 rectal ACF
  • 3.Willingness to provide written informed consent

排除标准

  • 1.Patients with lesion which preferred early resection.
  • 2.History of use of LTRA within 2months before trial entry.
  • 3.History of malignant disease within 5 yeears before trial entry.
  • 4.History of heart failure, renal failure, liver cirrhosis or chronic hepatic failure
  • 5.History of familial adenomatous polyposis, hereditary non-polyposis colorectal cancer and inflammatory bowel disease
  • 6.Pregnancy or possibility of pregnancy
  • 7.Contraindication to Montelukast
  • 8.Allergy to Montelukast
  • 9.Patients judged as inappropriate candidates for the trial by the investigators

研究者

发起方
Misawa Noboru

相似试验